Abstract

The cover picture shows the hypothetical binding motif of a novel potent protein kinase CK2 inhibitor, 4-bromo-3,8-dihydroxy-benzo[c]chromen-6-one, which shows a Ki value of 7 nM. CK2 is a ubiquitous, essential, and highly pleiotropic protein kinase, and abnormally high constitutive activity of this enzyme is thought to mediate its pathogenic potential in neoplasia and other diseases, such as viral infections and inflammatory diseases, like glomerulonephritis. Starting from the previous identification of highly active 3,8-dibromo-7-hydroxy-4-methylchromen-2-one and ellagic acid (Ki=20 nM and 60 nM, respectively), an X-ray-driven “cut & paste approach” was applied to design a novel series of urolithins as potent CK2 inhibitors. For more details, see the Full Paper by Stefano Moro et al. on p. 2273 ff.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.